The article describes political and advocacy activity in nonprofit human service organizations for children, elderly people, women, and people with disabilities. On the whole, the level of their political activity was found to be moderate, as perceived by the directors of the organizations. The main findings reveal a significant positive correlation between advocacy and political activity in nonprofit organizations and their perceived influence on setting the public agenda. Analysis of the findings indicates that the larger the number of volunteers in the organization, the greater the organization's political influence. In addition, it was found that the more dependent the organizations were on funding from local authorities, the lower the level of advocacy and political activity. The effectiveness of strategies used to attain political influence was also analyzed. The most effective strategy was exerting pressure on decision makers, both on the national and local levels.

No abstract

Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at the cost of significant life-threatening toxicity. The bispecific T-cell engager blinatumomab, recently approved for relapsed/refractory ALL, has a unique nonmyelotoxic toxicity profile. As blinatumomab causes B-cell depletion, the safety of its use during severe chemotherapy-induced toxicity is unclear. We report 11 pediatric patients with ALL, treated with blinatumomab following overwhelming chemotherapy-associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy. Blinatumomab can be considered for rare patients who cannot tolerate cytotoxic therapy. K E Y W O R D S blinatumomab, childhood acute lymphoblastic leukemia, immunotherapy, treatment-related toxicity Abbreviations: ALL, acute lymphoblastic leukemia; B-ALL, B-cell precursor acute lymphoblastic leukemia; DS, Down syndrome; MRD, minimal residual disease; R/R, relapsed/refractory.

Summary This study investigated the prevalence of inherited thrombophilia, risk of venous thromboembolism (VTE) and benefit of low molecular weight heparin prophylaxis in 476 Israeli children with acute lymphoblastic leukaemia (ALL) treated between 2004 and 2016. Thrombophilia was found in 15·5%. Arab children had a higher prevalence of F5 R506Q (factor V Leiden) than Jewish children (19·4% vs. 2·9%, P < 0·01). Patients with thrombophilia had higher VTE rates VTE (26·5% vs. 5·6%, P < 0·001). None of the thrombophilic children given prophylaxis had severe VTE. Routine evaluation for inherited thrombophilia followed by thromboprophylaxis when findings are positive may benefit at‐risk patients with ALL.

No abstract